[2] Treatment typically starts with 3 mg once daily for 30 days, then increases to 7 mg daily, with a possible further increase to 14 mg if needed for glycaemic control
In general, there is the cytoprotection concept: the described effects of the stable gastric pentadecapeptide BPC 157 (that has been found to be safe in ulcerative colitis trials, phase II, without a lethal dose (LD1) in the toxicology studies) were ascribed to its particular cytoprotective capabilities and pleiotropic background as an acting cytoprotective peptide that protects cells and may cure muscle disturbances in particular [11,12,13,14,24,25]
Methods Using a subset of Truveta Data, we identified adults who were prescribed a GLP-1 RA medication between January 01, 2024 and July 31, 2025
Interestingly, in pancreatic tissue of diabetic rats treated subcutaneously with a GLP-1R agonist for 10 weeks, SMA, collagen III, MMP2 and MMP9 were increased 43